Citations (30)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Carmine Valenza, Gabriele Antonarelli, Federica Giugliano, Gaetano Aurilio, Elena Verri, Alberto Briganti, Giuseppe Curigliano & Andrea Necchi. (2022) Emerging treatment landscape of non-muscle invasive bladder cancer. Expert Opinion on Biological Therapy 22:6, pages 717-734.
Read now
Read now
Articles from other publishers (29)
Francesca Sanguedolce, Ugo Giovanni Falagario, Magda Zanelli, Andrea Palicelli, Maurizio Zizzo, Gian Maria Busetto, Angelo Cormio, Giuseppe Carrieri & Luigi Cormio. (2024) Integrating the PD-L1 Prognostic Biomarker in Non-Muscle Invasive Bladder Cancer in Clinical Practice—A Comprehensive Review on State-of-the-Art Advances and Critical Issues. Journal of Clinical Medicine 13:8, pages 2182.
Crossref
Crossref
David Raja, Aishwarya Singh, Santosh Kurra, Brusabhanu Nayak, Seema Kaushal, Alpana Sharma & Prabhjot Singh. (2024) Clinical significance of blocking novel immune checkpoint B7-H4 in urothelial carcinoma of bladder as a potential therapeutic target. Medical Oncology 41:3.
Crossref
Crossref
Nicole Conci, Elisa Tassinari, Valentina Tateo, Matteo Rosellini, Andrea Marchetti, Costantino Ricci, Francesco Chessa, Matteo Santoni, Enrique Grande, Veronica Mollica & Francesco Massari. (2023) How Do Molecular Classifications Affect the Neoadjuvant Treatment of Muscle-Invasive Urothelial Carcinoma?. Molecular Diagnosis & Therapy 28:1, pages 37-51.
Crossref
Crossref
Berkha Rani, James J. Ignatz-Hoover, Priyanka S. Rana & James J. Driscoll. (2023) Current and Emerging Strategies to Treat Urothelial Carcinoma. Cancers 15:19, pages 4886.
Crossref
Crossref
Janos Revesz, Boglarka Posfai, Laszlo Pajor, Timea Papdan, Linda Varga, Viktor R. Paczona, Zoltan Varga, Farkas Sukosd & Aniko Maraz. (2023) Correlation between fibroblast growth factor receptor mutation, programmed death ligand-1 expression and survival in urinary bladder cancer based on real-world data. Pathology and Oncology Research 29.
Crossref
Crossref
Sumeyye Durur, Hakkı Uzun, Recep Bedir, Ihsan Nalkiran & Hatice Sevim Nalkiran. (2023) Prognostic importance of PD-L1 expression in bladder cancer patients. Journal of Cancer Research and Therapeutics 19:Suppl 2, pages S633-S638.
Crossref
Crossref
Utpal Kumar, Michael Leonard Anthony, Rishabh Sahai, Ankur Mittal, Prashant Durgapal & Sanjeev Kishore. (2021) Immunoexpression of PD-L1 and PD-1 and Its Clinicopathological Correlation in Urothelial Carcinomas. Journal of Laboratory Physicians 14:02, pages 197-201.
Crossref
Crossref
Katarzyna Uchimiak, Anna M. Badowska-Kozakiewicz, Aleksandra Sobiborowicz-Sadowska & Andrzej Deptała. (2022) Current State of Knowledge on the Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer Treatment: Approaches, Efficacy, and Challenges. Clinical Medicine Insights: Oncology 16, pages 117955492210998.
Crossref
Crossref
Brian W. Labadie, Arjun V. Balar & Jason J. Luke. (2021) Immune Checkpoint Inhibitors for Genitourinary Cancers: Treatment Indications, Investigational Approaches and Biomarkers. Cancers 13:21, pages 5415.
Crossref
Crossref
Gerald Bastian Schulz, Rumyana Todorova, Till Braunschweig, Severin Rodler, Yannic Volz, Lennert Eismann, Paulo Pfitzinger, Friedrich Jokisch, Alexander Buchner, Christian Stief, Doris Mayr & Jozefina Casuscelli. (2021) PD-L1 expression in bladder cancer: Which scoring algorithm in what tissue?. Urologic Oncology: Seminars and Original Investigations 39:10, pages 734.e1-734.e10.
Crossref
Crossref
Chien-Hsu Chen, Mu-Yao Tsai, Ping-Chia Chiang, Ming-Tse Sung, Hao-Lun Luo, Jau-Ling Suen, Eing-Mei Tsai & Po-Hui Chiang. (2021) Prognostic value of PD-L1 combined positive score in patients with upper tract urothelial carcinoma. Cancer Immunology, Immunotherapy 70:10, pages 2981-2990.
Crossref
Crossref
Francesco Rundo, Giuseppe Luigi Banna, Francesca Trenta & Sebastiano Battiato. (2021) Advanced Deep Network with Attention and Genetic-Driven Reinforcement Learning Layer for an Efficient Cancer Treatment Outcome Prediction. Advanced Deep Network with Attention and Genetic-Driven Reinforcement Learning Layer for an Efficient Cancer Treatment Outcome Prediction.
Mu-Yao Tsai, Ping-Chia Chiang, Chien-Hsu Chen, Ming-Tse Sung, Shun-Chen Huang, Jau-Ling Suen, Eing-Mei Tsai & Po-Hui Chiang. (2021) Comparison of the Prognostic Value of Ki-67 and Programmed Cell Death Ligand-1 in Patients with Upper Tract Urothelial Carcinoma. Journal of Clinical Medicine 10:16, pages 3728.
Crossref
Crossref
Kaiwei Yang, Wei Yu, Huanhuan Liu, Feng Ding, Yanrui Zhang, Yun Zhang, Wang Wang, Feng Lou, Shanbo Cao, Huina Wang & Zhisong He. (2021) Comparison of Genomic Characterization in Upper Tract Urothelial Carcinoma and Urothelial Carcinoma of the Bladder. The Oncologist 26:8, pages e1395-e1405.
Crossref
Crossref
Marina Mencinger, Dusan Mangaroski & Urska Bokal. (2021) Disease control with prior platinum-based chemotherapy is prognostic for survival in patients with metastatic urothelial cancer treated with atezolizumab in real-world practice. Radiology and Oncology 55:4, pages 491-498.
Crossref
Crossref
Paul Toren, Hervé Brisson, David Simonyan, Hélène Hovington, Louis Lacombe, Alain Bergeron & Yves Fradet. (2020) Androgen receptor and immune cell PD-L1 expression in bladder tumors predicts disease recurrence and survival. World Journal of Urology 39:5, pages 1549-1558.
Crossref
Crossref
Ioan Alin Nechifor-Boilă, Andrada Loghin, Adela Nechifor-Boilă, Myriam Decaussin-Petrucci, Septimiu Voidăzan, Bogdan Călin Chibelean, Orsolya Martha & Angela Borda. (2021) PD-L1 Expression in Muscle Invasive Urothelial Carcinomas as Assessed via Immunohistochemistry: Correlations with Specific Clinical and Pathological Features, with Emphasis on Prognosis after Radical Cystectomy. Life 11:5, pages 404.
Crossref
Crossref
Borivoj Golijanin, Boris Gershman, Andre De Souza, Ohad Kott, Benedito A. Carneiro, Anthony Mega, Dragan J. Golijanin & Ali Amin. (2021) p53 Expression, Programmed Death Ligand 1, and Risk Factors in Urinary Tract Small Cell Carcinoma. Frontiers in Oncology 11.
Crossref
Crossref
Florus C. de Jong, Vera C. Rutten, Tahlita C. M. Zuiverloon & Dan Theodorescu. (2021) Improving Anti-PD-1/PD-L1 Therapy for Localized Bladder Cancer. International Journal of Molecular Sciences 22:6, pages 2800.
Crossref
Crossref
Oliver Hale, Karl Patterson, Yizhen Lai, Yang Meng, Haojie Li, James Luke Godwin, Blanca Homet Moreno & Ronac Mamtani. (2021) Cost-effectiveness of Pembrolizumab versus Carboplatin-based Chemotherapy as First-line Treatment of PD-L1–positive Locally Advanced or Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Therapy in the United States. Clinical Genitourinary Cancer 19:1, pages e17-e30.
Crossref
Crossref
Carlos Stecca, Osama Abdeljalil & Srikala S. Sridhar. (2021) Metastatic Urothelial Cancer: a rapidly changing treatment landscape. Therapeutic Advances in Medical Oncology 13, pages 175883592110473.
Crossref
Crossref
Francesco Rundo, Giuseppe Luigi Banna, Francesca Trenta, Concetto Spampinato, Luc Bidaut, Xujiong Ye, Stefanos Kollias & Sebastiano Battiato. 2021. Pattern Recognition. ICPR International Workshops and Challenges. Pattern Recognition. ICPR International Workshops and Challenges
227
242
.
Bohyun Kim, Cheol Lee, Young A. Kim & Kyung Chul Moon. (2020) PD-L1 Expression in Muscle-Invasive Urinary Bladder Urothelial Carcinoma According to Basal/Squamous-Like Phenotype. Frontiers in Oncology 10.
Crossref
Crossref
Francesco Rundo, Giuseppe Luigi Banna, Luca Prezzavento, Francesca Trenta, Sabrina Conoci & Sebastiano Battiato. (2020) 3D Non-Local Neural Network: A Non-Invasive Biomarker for Immunotherapy Treatment Outcome Prediction. Case-Study: Metastatic Urothelial Carcinoma. Journal of Imaging 6:12, pages 133.
Crossref
Crossref
Qilai Long, Ai-Hong Ma, Hongyong Zhang, Zhixiu Cao, Roger Xia, Tzu-Yin Lin, Guru P. Sonpavde, Ralph de Vere White, Jianming Guo & Chong-Xian Pan. (2020) Combination of cyclin-dependent kinase and immune checkpoint inhibitors for the treatment of bladder cancer. Cancer Immunology, Immunotherapy 69:11, pages 2305-2317.
Crossref
Crossref
Ju-Yoon Yoon, Rakesh Nayyar, Graeme Quest, Dana Pabedinskas, Prodipto Pal, Ming-Sound Tsao, Joerg Schwock & Hyang-Mi Ko. (2020) PD-L1 lineage-specific quantification in malignant pleural effusions of lung adenocarcinoma by flow cytometry. Lung Cancer 148, pages 55-61.
Crossref
Crossref
Yuta Mukae, Yasuyoshi Miyata, Yuichiro Nakamura, Kyohei Araki, Asato Otsubo, Tsutomu Yuno, Kensuke Mitsunari, Tomohiro Matsuo, Kojiro Ohba & Hideki Sakai. (2020) Pathological roles of c‑Met in bladder cancer: Association with cyclooxygenase‑2, heme oxygenase‑1, vascular endothelial growth factor‑A and programmed death ligand�1. Oncology Letters.
Crossref
Crossref
Adriana Soares, Rafael Carmo, Catarina Rodrigues, Inês Teles Grilo & Enrique Grande. (2020) Chemotherapy Plus Immune Check-Point Inhibitors in Metastatic Bladder Cancer. Bladder Cancer 6:1, pages 1-8.
Crossref
Crossref
Ken Hatogai & Randy F. Sweis. 2020. Tumor Microenvironments in Organs. Tumor Microenvironments in Organs
275
290
.